Regeneron Pharmaceuticals will announce its financial and operating results for the second quarter of 2026 on July 30, before U.S. markets open. The company will hold a conference call and webcast at 8:30 AM Eastern Time the same day, accessible via its investor website. This update is important for investors tracking Regeneron's progress in biotechnology and drug development. A replay and transcript of the call will be available on Regeneron's website for 30 days.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Regeneron's cemdisiran, a potential first siRNA therapy for generalized myasthenia gravis (gMG), has been accepted for regulatory review by the FDA and EMA. The FDA is conducting a Priority Review with a decision expected by November 2026, while the ...
